2 weeks Ago By ABMN Staff
Ninepoint Partners LP purchased a new stake in Eli Lilly and Company ( NYSE:LLY – Free Report ) in the second quarter, Holdings Channel.com reports. The fund purchased 109 shares of the company’s stock, valued at approximately $99,000.
Several other large investors have also bought and sold shares of LLY. Core Wealth Advisors Inc. boosted its holdings in Eli Lilly and Company by 188.
2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares during the last quarter.
Lynx Investment Advisory bought a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $36,000. Frank Rimerman Advisors LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $37,000.
Finally, Redmont Wealth Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the first quarter valued at approximately $40,000. 82.53% of the stock is currently owned by institutional investors.
Eli Lilly and Company Stock Down 3.5 % Shares of NYSE LLY opened at $877.50 on Friday.
The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.
74. The company has a market cap of $833.98 billion, a P/E ratio of 129.
23, a P/E/G ratio of 2.78 and a beta of 0.42.
Eli Lilly and Company has a 52 week low of $516.57 and a 52 week high of $972.53.
The business has a 50-day simple moving average of $896.10 and a two-hundred day simple moving average of $842.91.
Wall Street Analyst Weigh In Several research analysts have weighed in on LLY shares. Citigroup began coverage on Eli Lilly and Company in a research report on Friday, September 13th. They issued a “buy” rating and a $1,060.
00 price objective on the stock. Berenberg Bank boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.
00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their price objective for the stock from $725.00 to $1,025.
00 in a report on Monday, August 12th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Finally, Barclays increased their target price on shares of Eli Lilly and Company from $913.
00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company.
According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $977.35. Get Our Latest Analysis on Eli Lilly and Company Insider Activity In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction on Wednesday, July 10th.
The stock was sold at an average price of $939.82, for a total value of $197,362,200.00.
Following the sale, the insider now owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link .
Insiders sold 423,559 shares of company stock worth $393,136,808 in the last three months. Corporate insiders own 0.13% of the company’s stock.
Eli Lilly and Company Profile ( Free Report ) Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. Read More Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Eli Lilly and Company ( NYSE:LLY – Free Report ). Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter .
.
